Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Total Current Liabilities (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Total Current Liabilities for 15 consecutive years, with $149.2 million as the latest value for Q1 2026.

  • For Q1 2026, Total Current Liabilities rose 4.28% year-over-year to $149.2 million; the TTM value through Mar 2026 reached $149.2 million, up 4.28%, while the annual FY2025 figure was $166.1 million, 17.98% up from the prior year.
  • Total Current Liabilities hit $149.2 million in Q1 2026 for Corcept Therapeutics, down from $166.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $172.3 million in Q3 2025 and bottomed at $49.1 million in Q2 2022.
  • Average Total Current Liabilities over 5 years is $110.0 million, with a median of $104.5 million recorded in 2023.
  • Year-over-year, Total Current Liabilities surged 129.65% in 2023 and then rose 3.56% in 2024.
  • Corcept Therapeutics' Total Current Liabilities stood at $72.5 million in 2022, then skyrocketed by 44.16% to $104.5 million in 2023, then surged by 34.7% to $140.8 million in 2024, then rose by 17.98% to $166.1 million in 2025, then fell by 10.18% to $149.2 million in 2026.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $149.2 million, $166.1 million, and $172.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.